584 related articles for article (PubMed ID: 14633738)
21. Molecular screening of interleukin-6 gene promoter and influence of -174G/C polymorphism on breast cancer.
Chérel M; Campion L; Bézieau S; Campone M; Charrier J; Gaschet J; Ricolleau G; Gouraud W; Charbonnel C; Jézéquel P
Cytokine; 2009 Sep; 47(3):214-23. PubMed ID: 19640729
[TBL] [Abstract][Full Text] [Related]
22. A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer.
Rokavec M; Schroth W; Amaral SM; Fritz P; Antoniadou L; Glavac D; Simon W; Schwab M; Eichelbaum M; Brauch H
Cancer Res; 2008 Dec; 68(23):9799-808. PubMed ID: 19047159
[TBL] [Abstract][Full Text] [Related]
23. Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy.
Gluz O; Mengele K; Schmitt M; Kates R; Diallo-Danebrock R; Neff F; Royer HD; Eckstein N; Mohrmann S; Ting E; Kiechle M; Poremba C; Nitz U; Harbeck N
J Clin Oncol; 2009 Dec; 27(36):6144-51. PubMed ID: 19901122
[TBL] [Abstract][Full Text] [Related]
24. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
25. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
26. A common interleukin-6 promoter polymorphism in patients with vulvar cancer.
Grimm C; Six L; Tomovski C; Speiser P; Joura E; Zeillinger R; Sliutz G; Reinthaller A; Hefler LA
J Soc Gynecol Investig; 2005 Dec; 12(8):617-20. PubMed ID: 16198606
[TBL] [Abstract][Full Text] [Related]
27. Association of interleukin-10 gene variation with breast cancer prognosis.
Gerger A; Renner W; Langsenlehner T; Hofmann G; Knechtel G; Szkandera J; Samonigg H; Krippl P; Langsenlehner U
Breast Cancer Res Treat; 2010 Feb; 119(3):701-5. PubMed ID: 19437115
[TBL] [Abstract][Full Text] [Related]
28. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes.
Truong PT; Berthelet E; Lee J; Kader HA; Olivotto IA
Cancer; 2005 May; 103(10):2006-14. PubMed ID: 15812825
[TBL] [Abstract][Full Text] [Related]
29. Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer.
Leppä S; Saarto T; Vehmanen L; Blomqvist C; Elomaa I
Breast Cancer Res Treat; 2005 Mar; 90(2):117-25. PubMed ID: 15803358
[TBL] [Abstract][Full Text] [Related]
30. Cytokine gene promoter polymorphisms and mortality in acute renal failure.
Jaber BL; Rao M; Guo D; Balakrishnan VS; Perianayagam MC; Freeman RB; Pereira BJ
Cytokine; 2004 Mar; 25(5):212-9. PubMed ID: 15036247
[TBL] [Abstract][Full Text] [Related]
31. The effects of interleukin 10 and interferon gamma cytokine gene polymorphisms on survival after autologous bone marrow transplantation for patients with breast cancer.
Wu JM; Bensen-Kennedy D; Miura Y; Thoburn CJ; Armstrong D; Vogelsang GB; Hess AD
Biol Blood Marrow Transplant; 2005 Jun; 11(6):455-64. PubMed ID: 15931634
[TBL] [Abstract][Full Text] [Related]
32. Genetic polymorphisms of eNOS, hormone receptor status, and survival of breast cancer.
Choi JY; Lee KM; Noh DY; Ahn SH; Lee JE; Han W; Jang IJ; Shin SG; Yoo KY; Hayes RB; Kang D
Breast Cancer Res Treat; 2006 Nov; 100(2):213-8. PubMed ID: 16821086
[TBL] [Abstract][Full Text] [Related]
33. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy.
Cheng YC; Rondón G; Yang Y; Smith TL; Gajewski JL; Donato ML; Shpall EJ; Jones R; Hortobagyi GN; Champlin RE; Ueno NT
Biol Blood Marrow Transplant; 2004 Nov; 10(11):794-804. PubMed ID: 15505610
[TBL] [Abstract][Full Text] [Related]
34. The interleukin-6 -174 G>C promoter polymorphism is associated with a higher risk of death after an acute coronary syndrome in male elderly patients.
Antonicelli R; Olivieri F; Bonafè M; Cavallone L; Spazzafumo L; Marchegiani F; Cardelli M; Recanatini A; Testarmata P; Boemi M; Parati G; Franceschi C
Int J Cardiol; 2005 Sep; 103(3):266-71. PubMed ID: 16098388
[TBL] [Abstract][Full Text] [Related]
35. The role of irradiation of the internal mammary lymph nodes in high-risk stage II to IIIA breast cancer patients after high-dose chemotherapy: a prospective sequential nonrandomized study.
Stemmer SM; Rizel S; Hardan I; Adamo A; Neumann A; Goffman J; Brenner HJ; Pfeffer MR
J Clin Oncol; 2003 Jul; 21(14):2713-8. PubMed ID: 12860949
[TBL] [Abstract][Full Text] [Related]
36. Polymorphisms in ER-alpha gene interact with estrogen receptor status in breast cancer survival.
Boyapati SM; Shu XO; Ruan ZX; Cai Q; Smith JR; Wen W; Gao YT; Zheng W
Clin Cancer Res; 2005 Feb; 11(3):1093-8. PubMed ID: 15709176
[TBL] [Abstract][Full Text] [Related]
37. Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience.
Colleoni M; Zahrieh D; Gelber RD; Holmberg SB; Mattsson JE; Rudenstam CM; Lindtner J; Erzen D; Snyder R; Collins J; Fey MF; Thürlimann B; Crivellari D; Murray E; Mendiola C; Pagani O; Castiglione-Gertsch M; Coates AS; Price K; Goldhirsch A
J Clin Oncol; 2005 Mar; 23(7):1390-400. PubMed ID: 15735115
[TBL] [Abstract][Full Text] [Related]
38. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
39. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy.
Kaplan HG; Malmgren JA; Atwood M
Breast J; 2009; 15(5):454-60. PubMed ID: 19671105
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of the immunocytochemical detection of contaminating tumor cells (CTC) in apheresis products of patients with high-risk breast cancer treated with high-dose chemotherapy and stem cell transplantation.
Solano C; Badia B; Lluch A; Marugan I; Benet I; Arbona C; Prosper F; García-Conde J
Bone Marrow Transplant; 2001 Feb; 27(3):287-93. PubMed ID: 11277176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
